BioCentury | Oct 19, 2009
Company News

Celsis, J O Hambro Capital Management Group deal

Hambro's investment bank North Atlantic Value LLP completed its previously announced acquisition of supply/service company Celsis for 232.5p per share in cash, or about £54.5 million ($85.8 million). Celsis CEO Jay LeCoque and CFO Christian...
BioCentury | May 26, 2003
Company News

Biocompatibles board of directors update

Biocompatibles International plc (LSE:BII), Farnham, U.K. Business: Biomaterial/Skin/Wound Resigning: James Hambro WIR Staff Dermatology...
BioCentury | Oct 13, 1997
Finance

Pipeline fill

Even though the industry raised $258 million last week, there's no shortage of financings in the pipeline. Bankers were tripping over themselves to get to the SEC, filing $308.2 million in biotech financings. The proposed...
BioCentury | Jul 21, 1997
Emerging Company Profile

Gene Logic Inc.

Gene Logic Inc. Columbia, Md. Technology: Accelerated Target Discovery platform centered on READS system (Restriction Enzyme Analysis of Differentially expressed Sequences) Disease focus: Central nervous system disorders; osteoporosis; prostate, breast and colon cancer; heart failure;...
BioCentury | Apr 7, 1997
Company News

SunPharm board of directors update

SunPharm Corp. (SUNP), Jacksonville, Fla. Business: Cancer, Infectious diseases/AIDS Appointed: Charles Dimmler III, president of Hambro Health International Inc. WIR Staff...
BioCentury | Feb 24, 1997
Finance

Sap for the maple leaf

The vast majority of Canadian biotech companies can't match the fund-raising power of big brother BioChem Pharma (BCHXF), which raised $159.3 million in a single follow-on offering last February. Nevertheless, like their U.S. counterparts, the...
Items per page:
1 - 6 of 6
BioCentury | Oct 19, 2009
Company News

Celsis, J O Hambro Capital Management Group deal

Hambro's investment bank North Atlantic Value LLP completed its previously announced acquisition of supply/service company Celsis for 232.5p per share in cash, or about £54.5 million ($85.8 million). Celsis CEO Jay LeCoque and CFO Christian...
BioCentury | May 26, 2003
Company News

Biocompatibles board of directors update

Biocompatibles International plc (LSE:BII), Farnham, U.K. Business: Biomaterial/Skin/Wound Resigning: James Hambro WIR Staff Dermatology...
BioCentury | Oct 13, 1997
Finance

Pipeline fill

Even though the industry raised $258 million last week, there's no shortage of financings in the pipeline. Bankers were tripping over themselves to get to the SEC, filing $308.2 million in biotech financings. The proposed...
BioCentury | Jul 21, 1997
Emerging Company Profile

Gene Logic Inc.

Gene Logic Inc. Columbia, Md. Technology: Accelerated Target Discovery platform centered on READS system (Restriction Enzyme Analysis of Differentially expressed Sequences) Disease focus: Central nervous system disorders; osteoporosis; prostate, breast and colon cancer; heart failure;...
BioCentury | Apr 7, 1997
Company News

SunPharm board of directors update

SunPharm Corp. (SUNP), Jacksonville, Fla. Business: Cancer, Infectious diseases/AIDS Appointed: Charles Dimmler III, president of Hambro Health International Inc. WIR Staff...
BioCentury | Feb 24, 1997
Finance

Sap for the maple leaf

The vast majority of Canadian biotech companies can't match the fund-raising power of big brother BioChem Pharma (BCHXF), which raised $159.3 million in a single follow-on offering last February. Nevertheless, like their U.S. counterparts, the...
Items per page:
1 - 6 of 6